KyungdongPharm Q3 revenue KRW 53.1 billion, operating profit KRW 3.9 billion, net loss KRW 1.8 billion
KAI summary · Not investment advice
Kyungdong Pharm sold KRW 53.1 billion in Q3 and earned KRW 3.9 billion from its main business, up 25.6% from a year earlier and up 4.7% from the prior quarter.
Operating profit · 3 months
KRW 3.9 billion
Key facts
- Revenue (3 months)
- KRW 53.1 billion
- Net income (3 months)
- KRW -1.8 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 48.9 billion
- Revenue (year to date)
- KRW 153.1 billion
- Operating profit (prior-year 3 months)
- KRW 3.1 billion
- Operating profit (year to date)
- KRW 10.0 billion
- Net income (prior-year 3 months)
- KRW 4.4 billion
- Net income (year to date)
- KRW 8.6 billion
Commentary
AI commentary · Not investment advice
What happened
Kyung Dong Pharmaceutical reported its consolidated results for the 3rd quarter of 2026. Sales for the latest 3 months were KRW 53.07 billion. Operating profit (profit from the core business) was KRW 3.88 billion. Net income (the final profit after taxes and all costs) was a loss of KRW 1.84 billion, a swing to a loss.
In the company's terms
Sales were up 8.6% from the same 3 months a year earlier, and up 1.5% from the previous quarter. Operating profit was up 25.6% from a year earlier, and up 4.7% from the previous quarter. Net income was KRW 4.41 billion a year earlier. The previous quarter was profitable, so the quarter-on-quarter change is a swing to a loss.
What changes for shareholders
For the year to date (January 1 to September 30), sales were KRW 153.14 billion. Operating profit was KRW 9.99 billion. Net income was KRW 8.64 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist